article thumbnail

Clustering Fragment Screening Hits With a Self-Organizing Map

Practical Cheminformatics

Clustering Fragment Screening Hits With a Self-Organizing Map (SOM) In a paper, " Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking ", published last year by scientists from UCSF and the Diamond Light Source, the authors reported more than 200 structures of fragments bound (..)

article thumbnail

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

Drug Discovery Today

Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431; Inhibitors discovered at Domainex via virtual and fragment screening

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

In terms of compound libraries, we have a high-throughput screening library of about 200,000 ligands. For fragment screening, which are much smaller compounds, we have a library of about 3000 fragments. We can screen with many different formats and modalities.

article thumbnail

Practical Cheminformatics - The Directory

Practical Cheminformatics

Adding Chemical Structures to a Recent COVID-19 Drug Repurposing Dataset Filtering Chemical Libraries Data Visualization / Plotting A Collection of Things I Frequently Forget How To Do With Seaborn Scatterplots Interactive Plots with Chemical Structures Visualizing Chemical Space Plotting Distributions Molecular Modeling Exploring the SARS-CoV-2 Main (..)

article thumbnail

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Covalent Modifiers

Herein, we describe a covalent fragment screen that identified the chloroacetohydrazide scaffold as a covalent UCHL1 inhibitor. Subsequent optimization provided an improved fragment with single-digit micromolar potency against UCHL1 and selectivity over the closely related UCHL3.

article thumbnail

Sygnature Discovery acquires Peak Proteins

Sygnature Discovery

Their world-class expertise in protein crystallography will enhance our fragment screening and analysis activities, as well as our structure-based drug design work.” Mark Abbott, CEO of Peak Proteins, commented: “We have always valued Sygnature Discovery’s support and are now really pleased to be joining them.

article thumbnail

Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32

Molecular Design

In the fourth of his rules for air fighting , ‘Sailor’ Malan (readers may also be interested in his insights into fragment screening library design ) asserts that “height gives you the initiative” which can be adapted for drug design as “affinity gives you the initiative”.